Myasthenia Gravis News
Our mission is to provide you with the latest science, research, and clinical updates on Myasthenia Gravis. We are a free online resource dedicated to serving the patient community.
Outlet metrics
Global
#803921
United States
#216460
Health/Health Conditions and Concerns
#560
Articles
-
1 week ago |
myastheniagravisnews.com | Mark Harrington
Living with myasthenia gravis (MG) has changed important parts of my life. It has taken things from me that I thought were permanent, such as my physical strength. My previous ability to plan my days with confidence no longer exists. Most difficult of all, MG has made me distrust our healthcare system here in the U.S.However, a new me has arisen phoenixlike from the ashes of my pre-MG life. Upon reflection, I see the new me as a better man.
-
3 weeks ago |
myastheniagravisnews.com | Mark Harrington
Living with a rare disease is difficult enough, but in the United States, patients fight not only their illness, but also the healthcare system that’s supposed to help them. I was diagnosed with myasthenia gravis (MG) five years ago this month. Managing it requires specialized care, regular treatment, and access to breakthrough medications.
-
1 month ago |
myastheniagravisnews.com | Steve Bryson
Using tears to test for self-reactive antibodies to help diagnose ocular myasthenia gravis (OMG) is more accurate than using blood samples, according to a study that found nearly all patients who tested negative for these antibodies in the blood had a positive result in tears. “Tear-based testing offers a promising alternative for diagnosing [blood]-negative OMG cases,” the researchers wrote.
-
1 month ago |
myastheniagravisnews.com | Marisa Wexler
A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common among girls than boys, and in Black children over white children. “Understanding the incidence and prevalence of JMG is crucial for optimizing its management.
-
1 month ago |
myastheniagravisnews.com | Steve Bryson
Enrollment is open in an investigator-initiated clinical trial to evaluate cell therapy NKX019 in people with myasthenia gravis (MG). Nkarta, the therapy’s developer, made the announcement in a company press release. Researchers at the University of California, Irvine, and the University of Kansas Medical Center are leading the open-label Phase 1 trial, which was given the go-ahead by the U.S. Food and Drug Administration late last year.
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Website
http://myastheniagravisnews.comTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →